Clinical Trials
22 trialsNCT01496976 2025-12-19
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01919619 2024-12-03
Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00792077 2021-07-01
A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01497496 2021-04-27
Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00602836 2020-01-27
Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
Phase 2 Completed
NCT02538965 2020-01-07
A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Celgene
Phase 2 Completed
NCT01743859 2019-10-08
Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia
University of Colorado, Denver
Phase 2 Completed
NCT00860457 2018-11-21
Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)
Georgetown University
Phase 2 Completed
NCT00352001 2018-09-19
Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT00535873 2018-08-21
Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01442714 2018-01-03
Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS
Stanford University
Phase 2 Terminated
NCT01034592 2017-08-02
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia
Stanford University
Phase 1 Terminated
NCT00096044 2017-07-11
Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Roswell Park Cancer Institute
Phase 2 Completed
NCT01011894 2017-05-18
Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00890552 2017-03-22
A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis
Stanford University
Phase NA Completed
NCT01038635 2017-02-10
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01600053 2016-12-15
Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia
University of California, San Diego
Phase 2 Terminated
NCT01401322 2016-11-28
Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Stanford University
Phase 2 Terminated
NCT00759603 2015-08-27
Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00267059 2012-08-07
Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01222195 2012-08-07
Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00179621 2011-04-14
Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality
Celgene
Phase 3 Completed